trending Market Intelligence /marketintelligence/en/news-insights/trending/gdbp_34dywbfokrrxo-hgw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Sunovion, Novartis sign license agreement for 3 pulmonary disease drugs

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Sunovion, Novartis sign license agreement for 3 pulmonary disease drugs

Sunovion Pharmaceuticals Inc. and Novartis AG signed an exclusive license agreement for U.S. commercialization rights to three approved chronic obstructive pulmonary disease drugs.

Under the deal, Sunovion will hold exclusive commercialization rights to Utibron Neohaler, Seebri Neohaler and Arcapta Neohaler in the U.S. Novartis will continue to manufacture the three drugs.

The U.S. FDA approved Utibron Neohaler and Seebri Neohaler in 2015. Sunovion plans to bring these two drugs to market in 2017. Arcapta Neohaler was approved in the U.S. in 2011 and arrived in the market in 2012.

Sunovion Pharmaceuticals is a unit of Sumitomo Dainippon Pharma Co. Ltd.